These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 36423542)

  • 61. Escin augments the efficacy of gemcitabine through down-regulation of nuclear factor-κB and nuclear factor-κB-regulated gene products in pancreatic cancer both in vitro and in vivo.
    Wang YW; Wang SJ; Zhou YN; Pan SH; Sun B
    J Cancer Res Clin Oncol; 2012 May; 138(5):785-97. PubMed ID: 22270965
    [TBL] [Abstract][Full Text] [Related]  

  • 62. DUSP1 is a novel target for enhancing pancreatic cancer cell sensitivity to gemcitabine.
    Liu F; Gore AJ; Wilson JL; Korc M
    PLoS One; 2014; 9(1):e84982. PubMed ID: 24409315
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Chrysin induces autophagy-dependent ferroptosis to increase chemosensitivity to gemcitabine by targeting CBR1 in pancreatic cancer cells.
    Zhou L; Yang C; Zhong W; Wang Q; Zhang D; Zhang J; Xie S; Xu M
    Biochem Pharmacol; 2021 Nov; 193():114813. PubMed ID: 34673014
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Deoxyelephantopin induces apoptosis via oxidative stress and enhances gemcitabine sensitivity
    Ji D; Zhong X; Huang P; Kang P; Leng K; Zheng W; Wang Z; Xu Y; Cui Y
    Aging (Albany NY); 2020 Jun; 12(11):11116-11138. PubMed ID: 32526702
    [TBL] [Abstract][Full Text] [Related]  

  • 65. STAT3 inhibition enhances gemcitabine sensitivity in pancreatic cancer by suppressing EMT, immune escape and inducing oxidative stress damage.
    Guo H; Hu Z; Yang X; Yuan Z; Gao Y; Chen J; Xie L; Chen C; Guo Y; Bai Y
    Int Immunopharmacol; 2023 Oct; 123():110709. PubMed ID: 37515849
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Berbamine enhances the antineoplastic activity of gemcitabine in pancreatic cancer cells by activating transforming growth factor-β/Smad signaling.
    Jin X; Wu Y
    Anat Rec (Hoboken); 2014 May; 297(5):802-9. PubMed ID: 24619961
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Depletion of pro-oncogenic RUNX2 enhances gemcitabine (GEM) sensitivity of p53-mutated pancreatic cancer Panc-1 cells through the induction of pro-apoptotic TAp63.
    Ozaki T; Nakamura M; Ogata T; Sang M; Yoda H; Hiraoka K; Sang M; Shimozato O
    Oncotarget; 2016 Nov; 7(44):71937-71950. PubMed ID: 27713122
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer.
    Banerjee S; Zhang Y; Ali S; Bhuiyan M; Wang Z; Chiao PJ; Philip PA; Abbruzzese J; Sarkar FH
    Cancer Res; 2005 Oct; 65(19):9064-72. PubMed ID: 16204081
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Effects of ribosomal associated protein hnRNP D in gemcitabine-resistant pancreatic cancer.
    Wang C; Huang H
    Biochem Biophys Res Commun; 2021 Nov; 579():181-187. PubMed ID: 34624736
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Nuclear factor-kappaB p65/relA silencing induces apoptosis and increases gemcitabine effectiveness in a subset of pancreatic cancer cells.
    Pan X; Arumugam T; Yamamoto T; Levin PA; Ramachandran V; Ji B; Lopez-Berestein G; Vivas-Mejia PE; Sood AK; McConkey DJ; Logsdon CD
    Clin Cancer Res; 2008 Dec; 14(24):8143-51. PubMed ID: 19088029
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Perifosine inhibits S6K1-Gli1 signaling and enhances gemcitabine-induced anti-pancreatic cancer efficiency.
    Xin Y; Shen XD; Cheng L; Hong DF; Chen B
    Cancer Chemother Pharmacol; 2014 Apr; 73(4):711-9. PubMed ID: 24519751
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Local Delivery of Gemcitabine Inhibits Pancreatic and Cholangiocarcinoma Tumor Growth by Promoting Epidermal Growth Factor Receptor Degradation.
    Jang SI; Fang S; Baek YY; Lee DH; Na K; Lee SY; Lee DK
    Int J Mol Sci; 2020 Feb; 21(5):. PubMed ID: 32111094
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Antitumor effect of trastuzumab for pancreatic cancer with high HER-2 expression and enhancement of effect by combined therapy with gemcitabine.
    Kimura K; Sawada T; Komatsu M; Inoue M; Muguruma K; Nishihara T; Yamashita Y; Yamada N; Ohira M; Hirakawa K
    Clin Cancer Res; 2006 Aug; 12(16):4925-32. PubMed ID: 16914581
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Circ_0092367 Inhibits EMT and Gemcitabine Resistance in Pancreatic Cancer via Regulating the miR-1206/ESRP1 Axis.
    Yu S; Wang M; Zhang H; Guo X; Qin R
    Genes (Basel); 2021 Oct; 12(11):. PubMed ID: 34828307
    [TBL] [Abstract][Full Text] [Related]  

  • 75. TIMP1 down-regulation enhances gemcitabine sensitivity and reverses chemoresistance in pancreatic cancer.
    Tan Y; Li X; Tian Z; Chen S; Zou J; Lian G; Chen S; Huang K; Chen Y
    Biochem Pharmacol; 2021 Jul; 189():114085. PubMed ID: 32522594
    [TBL] [Abstract][Full Text] [Related]  

  • 76. aPKCι promotes gallbladder cancer tumorigenesis and gemcitabine resistance by competing with Nrf2 for binding to Keap1.
    Tian L; Lu Y; Yang T; Deng Z; Xu L; Yao W; Ma C; Li X; Zhang J; Liu Y; Wang J
    Redox Biol; 2019 Apr; 22():101149. PubMed ID: 30822690
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Chemoresistance Transmission via Exosome-Mediated EphA2 Transfer in Pancreatic Cancer.
    Fan J; Wei Q; Koay EJ; Liu Y; Ning B; Bernard PW; Zhang N; Han H; Katz MH; Zhao Z; Hu Y
    Theranostics; 2018; 8(21):5986-5994. PubMed ID: 30613276
    [No Abstract]   [Full Text] [Related]  

  • 78. Monensin inhibits cell proliferation and tumor growth of chemo-resistant pancreatic cancer cells by targeting the EGFR signaling pathway.
    Wang X; Wu X; Zhang Z; Ma C; Wu T; Tang S; Zeng Z; Huang S; Gong C; Yuan C; Zhang L; Feng Y; Huang B; Liu W; Zhang B; Shen Y; Luo W; Wang X; Liu B; Lei Y; Ye Z; Zhao L; Cao D; Yang L; Chen X; Haydon RC; Luu HH; Peng B; Liu X; He TC
    Sci Rep; 2018 Dec; 8(1):17914. PubMed ID: 30559409
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Combined treatment with tamoxifen and a fusicoccin derivative (ISIR-042) to overcome resistance to therapy and to enhance the antitumor activity of 5-fluorouracil and gemcitabine in pancreatic cancer cells.
    Miyake T; Honma Y; Urano T; Kato N; Suzumiya J
    Int J Oncol; 2015 Jul; 47(1):315-24. PubMed ID: 25936828
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Cucurbitacin B induces apoptosis by inhibition of the JAK/STAT pathway and potentiates antiproliferative effects of gemcitabine on pancreatic cancer cells.
    Thoennissen NH; Iwanski GB; Doan NB; Okamoto R; Lin P; Abbassi S; Song JH; Yin D; Toh M; Xie WD; Said JW; Koeffler HP
    Cancer Res; 2009 Jul; 69(14):5876-84. PubMed ID: 19605406
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.